Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


Revenue 2017


The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Shire's 2013 CNS, immunology and metabolic's sales performance.


Microsoft brings its AI network to cardiology

Microsoft brings its AI network to cardiology

technologies. The company also recently started working with Shire to look at how technology could be used to accelerate the time it takes to diagnose rare diseases in children. .

Bridging pharma’s digital gap

Bridging pharma’s digital gap Naomi O’Connell, Shire’s head of advertising and promotion, global operations, admits that the digitisation process needs to improve throughout the biopharma industry.

Shire teams up with Microsoft and EURORDIS for rare disease project

Shire teams up with Microsoft and EURORDIS for rare disease project Will work to accelerate the time to diagnosis for children. Shire has formed a strategic alliance with Microsoft and the European rare diseases patient group organisation EURORDIS to accelerate the time ... The Commission will be jointly led by Shire’s

Deal Watch January 2018

quite as fast as Shire's move to take over Baxalta when it was spun out of Baxter in July 2015).

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts


Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...